The immunogenic effects of platinum compounds include the following four aspects (3, 39) (Figure 1): (I) the induction of ICD; (II) the downregulation of PD-L1 and PD-L2 on DCs and the improvement in their T-cell activation potential; (III) the inactivation of the STAT pathway, thereby decreasing the expression of PD-L2 on cancer cells; and (IV) the upregulation of the M6P receptor on tumor cells, leading to tumor cell killing by the granzyme-B of activated T cells. Here, PDCD1LG2 is linked to cancer.